Anticoagulant activity of apixaban can be estimated by multiple regression analysis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Arrhythmia"
DOI: 10.1002/joa3.12435
Abstract: Information on apixaban anticoagulant activity is required to prevent major bleeding or thrombosis during its use. read more here.
Keywords: estimated multiple; apixaban estimated; activity apixaban; anticoagulant activity ... See more keywords
The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al.
Sign Up to like & getrecommendations! Published in 2017 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.4163
Abstract: Hellfritzsch et al. discuss an apparent lack of consistency in reporting of renal elimination data among novel oral anticoagulant drugs: with a focus on apixaban.1 We would like to provide the totality of data that… read more here.
Keywords: apixaban; renal clearance; clearance; renal impairment ... See more keywords
The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-019-00348-2
Abstract: BackgroundThis was an open-label, phase I, nonrandomized, single-sequence, crossover study to evaluate the effect of concomitant administration of multiple doses of clarithromycin on the single-dose exposure, safety, and tolerability of apixaban in healthy subjects.MethodsIn total,… read more here.
Keywords: sequence crossover; administration; single sequence; clarithromycin ... See more keywords
Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Sign Up to like & getrecommendations! Published in 2017 at "Thrombosis research"
DOI: 10.1016/j.thromres.2017.09.001
Abstract: Dabigatran etexilate, rivaroxaban and apixaban (DOACs) are widely used and measurement of their concentration is desirable in certain clinical situations. Target-specific assays are available but limited information exists on their performance especially in their ability… read more here.
Keywords: multicenter; dabigatran rivaroxaban; target specific; rivaroxaban apixaban ... See more keywords
A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2019.1676723
Abstract: ABSTRACT Introduction: The non-vitamin K antagonist oral anticoagulants (NOACs) are changing the landscape for stroke prevention in atrial fibrillation (AF) and prevention or treatment of venous thromboembolism (VTE). In patients with AF and concomitant acute… read more here.
Keywords: atrial fibrillation; treatment; safety; acute coronary ... See more keywords
Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.0401
Abstract: Vitamin K antagonists (VKA) and non-VKA oral anticoagulants (NOACs) are used to prevent thromboembolic conditions in patients with atrial fibrillation (AF). Unlike VKA, NOACs have fixed dosage schemes, do not require regular laboratory tests, and… read more here.
Keywords: rivaroxaban; vka; major bleeding; study ... See more keywords
P1255Comparative safety and effectiveness of standard doses of apixaban versus dabigatran, rivaroxaban, and VKAs in non-valvular atrial fibrillation patients in France: the NAXOS study
Sign Up to like & getrecommendations! Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz748.0213
Abstract: Real-world data comparing all available oral anticoagulants (OAC) on a nationwide scale (i.e. in France: apixaban, rivaroxaban, dabigatran and vitamin K antagonists – VKAs) are lacking. In everyday practice, oral anticoagulants are often underdosed, which… read more here.
Keywords: rivaroxaban; safety; vkas; apixaban ... See more keywords
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
Sign Up to like & getrecommendations! Published in 2018 at "Heart"
DOI: 10.1136/heartjnl-2018-313351
Abstract: Objectives Compare the effect of apixaban and warfarin on coagulation and primary haemostasis biomarkers in atrial fibrillation (AF). Methods The biomarker substudy from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial… read more here.
Keywords: atrial fibrillation; apixaban compared; treatment; effect apixaban ... See more keywords
ADPKD, COVID-19, and Apixaban: The Treacherous Intracystic Bleeding − A Letter on Apixaban Causing Hepatic Cystic Bleeding by Shehi et al.
Sign Up to like & getrecommendations! Published in 2022 at "Case Reports in Gastroenterology"
DOI: 10.1159/000521812
Abstract: Shehi et al. [1] report on a 69-year-old Hispanic man who presented to the hospital with complaints of right upper quadrant pain for the past 3 days without any history of trauma to the abdomen.… read more here.
Keywords: adpkd covid; apixaban; covid apixaban; treacherous intracystic ... See more keywords
Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
Sign Up to like & getrecommendations! Published in 2017 at "Thrombosis and haemostasis"
DOI: 10.1160/th17-03-0193
Abstract: Currently, low molecular weight heparin (LMWH) is the guideline endorsed treatment of patients with cancer associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, there are limited data supporting its… read more here.
Keywords: trial; adam vte; thromboembolism; venous thromboembolism ... See more keywords
Letter by Cheen Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States".
Sign Up to like & getrecommendations! Published in 2019 at "Circulation"
DOI: 10.1161/circulationaha.118.038646
Abstract: March 19, 2019 1561 McVin Hua Heng Cheen, BSc (Pharm) (Hons), PhD To the Editor: I read with great interest the article by Siontis et al1 published in Circulation. As mentioned in the commentary, current… read more here.
Keywords: time; time bias; immortal time; apixaban ... See more keywords